Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is a Healthcare company (Biotechnology) with a market capitalization of $286M. The Maz Rating grades it against the other companies in its sector.
Fulcrum Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.75, Fulcrum Therapeutics, Inc. trades at 0.9x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -23.6%, return on invested capital of -24.7% and a free cash flow yield of -22.9%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 36.19. Over the past 52 weeks the share price ranged from $2.83 to $15.74, with a beta of 2.77.
Fulcrum Therapeutics, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 7 Buy, 7 Hold and 3 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.